Filing Flows › Comparisons › TVTX vs AMPH
Travere Therapeutics vs Amphastar Pharmaceuticals: TVTX and AMPH compared
Travere Therapeutics is the larger company: $225M of revenue in its latest quarter (Q3 2026) against $208M for Amphastar Pharmaceuticals (Q3 2026). Travere Therapeutics is growing faster (+36% against +8% a year earlier). Amphastar Pharmaceuticals is more profitable, with an operating margin of 24.5% against -30.3%.
Where the money goes: TVTX and AMPH
Travere Therapeutics (TVTX) · Q3 2026
Travere Therapeutics, Q3 2026: revenue $225M (+36% year over year), operating margin -30.3%, net loss $52.3M, operating cash flow $98.2M. The chart follows the revenue to costs, profit and cash.
Amphastar Pharmaceuticals (AMPH) · Q3 2026
Amphastar Pharmaceuticals, Q3 2026: revenue $208M (+8% year over year), operating margin 24.5%, net earnings $37.8M, operating cash flow $43.3M. The chart follows the revenue to costs, profit and cash.
| Travere Therapeutics (TVTX) | Amphastar Pharmaceuticals (AMPH) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $225M | $208M |
| Revenue growth, Y/Y | +36% | +8% |
| Gross margin | — | 48.0% |
| Operating margin | -30.3% | 24.5% |
| Net earnings | −$52.3M | $37.8M |
| Net margin | -23.3% | 18.2% |
| Operating cash flow | $98.2M | $43.3M |
| Free cash flow | — | $33.4M |
| Market value | — | $1.2B |
| P/E | — | 15.0× |
| Analysts’ mean target | — | $22.50 |
Where the revenue comes from
Travere Therapeutics
- Total net product sales: $220M (98%)
- License and collaboration revenue: $4.4M (2%)
Questions
Which is bigger, Travere Therapeutics or Amphastar Pharmaceuticals?
Travere Therapeutics is the larger company: $225M of revenue in its latest quarter (Q3 2026) against $208M for Amphastar Pharmaceuticals (Q3 2026).
Is Travere Therapeutics or Amphastar Pharmaceuticals growing faster?
Travere Therapeutics is growing faster (+36% against +8% a year earlier).
Which is more profitable, Travere Therapeutics or Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals is more profitable, with an operating margin of 24.5% against -30.3%.
More: Travere Therapeutics earnings · how Travere Therapeutics makes money · Amphastar Pharmaceuticals earnings · how Amphastar Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 2, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.